Search

Your search keyword '"DeLima, Marcos"' showing total 14 results
Start Over Author "DeLima, Marcos" Language english
14 results on '"DeLima, Marcos"'

2. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia

Author

Hamilton, Betty Ky, Rybicki, Lisa, Abounader, Donna, Adekola, Kehinde, Advani, Anjali, Aldoss, Ibrahim, Bachanova, Veronika, Bashey, Asad, Brown, Stacey, DeLima, Marcos, Devine, Steven, Flowers, Christopher R., Ganguly, Siddharth, Jagasia, Madan, Kennedy, Vanessa E., Kim, Dennis Dong Hwan, McGuirk, Joseph, Pullarkat, Vinod, Romee, Rizwan, Sandhu, Karamjeet, Smith, Melody, Ueda, Masumi, Viswabandya, Auro, Vu, Khoan, Wall, Sarah, Zeichner, Simon B., Perales, Miguel-Angel, and Majhail, Navneet S.

Published
2017
Full Text
View/download PDF

3. Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.

Author

Faisal, Muhammad Salman, Hanel, Walter, Voorhees, Timothy, Li, Rui, Huang, Ying, Khan, Abdullah, Bond, David, Sawalha, Yazeed, Reneau, John, Alinari, Lapo, Baiocchi, Robert, Christian, Beth, Maddocks, Kami, Efebera, Yvonne, Penza, Sam, Saad, Ayman, Brammer, Jonathan, DeLima, Marcos, Jaglowski, Samantha, and Epperla, Narendranath

Subjects
HEMATOPOIETIC stem cell transplantation, HODGKIN'S disease, GRAFT versus host disease
Abstract

Background: Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time‐trend analysis of R/R HL patients who received allogeneic hematopoietic cell transplantation (allo‐HCT) at our center from 2001–2017. Methods: The patients were divided into two distinct treatment cohorts: era1 (2001–2010), and era2 (2011–2017). The primary endpoint was overall survival (OS). Secondary endpoints included progression‐free survival (PFS), non‐relapse mortality (NRM), and cumulative incidence of acute and chronic graft versus host disease (GVHD). Results: Among the 51 patients included in the study, 29 were in era1, and 22 were in era2. There was decreased use of myeloablative conditioning in era2 (18% vs. 31%) compared to era1 and 95% of patients in era2 previously received brentuximab Vedotin (BV). Haploidentical donors were seen exclusively in era2 (0% vs. 14%) and more patients received alternative donor transplants (7% vs. 32%) in era2. The 4‐year OS (34% vs. 83%, p < 0.001) and 4‐year PFS (28% vs. 62%, p = 0.001) were significantly inferior in era1 compared to era2. The incidence of 1‐year NRM was lower in era2 compared to era1 (5% vs. 34%, p = 0.06). The cumulative incidence of acute GVHD at day 100 was similar in both eras (p = 0.50), but the incidence of chronic GVHD at 1 year was higher in era2 compared to era1 (55% vs. 21%, p = 0.03). Conclusions: Despite the advent of novel therapies, allo‐HCT remains an important therapeutic option for patients with R/R HL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Author

Porter, David L., Alyea, Edwin P., Antin, Joseph H., DeLima, Marcos, Estey, Eli, Falkenburg, J.H. Frederik, Hardy, Nancy, Kroeger, Nicolaus, Leis, Jose, Levine, John, Maloney, David G., Peggs, Karl, Rowe, Jacob M., Wayne, Alan S., Giralt, Sergio, Bishop, Michael R., and van Besien, Koen

Published
2010
Full Text
View/download PDF

7. A Phase 1 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib (MLN9708) for Relapsed/ Refractory Acute Myeloid Leukemia (AML)

Author

Advani, Anjali S., Cooper, Brenda, Elson, Paul, Mukherjee, Sudipto, Fensterl, Jaime, Gerds, Aaron T., Caimi, Paolo F., Tomlinson, Ben K., Malek, Ehsan, Little, Jane A., Rush, Mary Lynn, Bogati, Samjhana, Parsons, Eric, Kane, Donna, Carraway, Hetty E., Nazha, Aziz, Hamilton, Betty K., Sobecks, Ronald, Bevier, Barbara, Goebel, Christopher, Zimmerman, Cassie, Nielsen, Alek d, Hirsch, Cassandra M., Maciejewski, Jaroslaw P., Kalaycio, Matt, deLima, Marcos, Jacobberger, James, Woost, Philip, and Sekeres, Mikkael A.

Published
2016
Full Text
View/download PDF

8. Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Author

Garcia-Manero, Guillermo, Tambaro, Francesco Paolo, Bekele, Nebiyou, Yang, Hui, Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Kadia, Tapan, Konopleva, Marina, Faderl, Stefan, Cortes, Jorge E., Brandt, Mark, Hu, Yumin, McCue, Deborah, Newsome, Willie Mae, Pierce, Sherry, DeLima, Marcos, and Kantarjian, Hagop M.

Published
2011
Full Text
View/download PDF

9. Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Author

Warlick, Erica D, McClune, Brian, Pedersen, Tanya L., Awn, Kwang W, Antin, Joseph H., Cahn, Jean-Yves, DeLima, Marcos, Gupta, Vikas, Marks, David I, Bunjes, Donald, DiPersio, John F., Devine, Steven, and Weisdorf, Daniel J.

Published
2011
Full Text
View/download PDF

10. Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia.

Author

DeLima, Marcos, Albitar, Maher, O'Brien, Susan, Pierce, Sherry, Kantarjian, Hagop, Andreeff, Michael, Fayad, Luis, Keating, Michael, Estey, Elihu, DeLima, M, Albitar, M, O'Brien, S, Pierce, S, Kantarjian, H, Andreeff, M, Fayad, L, Keating, M, and Estey, E

Subjects
*LEUKEMIA diagnosis, *BONE marrow, *COMPARATIVE studies, *DIFFERENTIAL diagnosis, *IMMUNOPHENOTYPING, *LEUKEMIA, *RESEARCH methodology, *MEDICAL cooperation, *MEDICAL referrals, *RESEARCH, *EVALUATION research, *CROSS-sectional method
Abstract

Purpose: To analyze the rates of concordance in the diagnosis of various hematological malignancies among patients referred to a tertiary cancer center, comparing the referring diagnosis with the final diagnosis at the M.D. Anderson Cancer Center.Patients and Methods: This was a cross-sectional study analyzing the 409 patients referred to the M.D. Anderson Leukemia Service in 1995 in whom a bone marrow examination was performed by the referring physician and in whom this examination was repeated at our institution. We also analyzed 100 cases, including 84 of the 409 referred patients for whom the diagnostic outside bone marrow slide had been sent for review.Results: The overall concordance rate was 73%. In 18% discordances were present and considered of major importance (affecting treatment and/or prognosis) while in 9% there were minor discordances. Major discordance rates were 2% for chronic lymphocytic leukemic leukemia and 5% for chronic myelogenous leukemia, but 29% for acute myelogenous leukemia (79 patients), 43% for acute promyelocytic leukemia (7 patients), 19% for acute lymphocytic leukemia (42 patients), 57% for hairy cell leukemia (7 patients), and 23% for the myelodysplastic syndromes (75 patients). The concordance rate was 76% in the 100 cases in which bone marrow specimens permitted comparison of the morphologic diagnosis made by M.D. Anderson and the referring physician using the same slide, with a rate of 75% in the acute leukemias as finally diagnosed at our institution.Conclusion: Although in the majority of cases the referring physicians and the specialty service agreed on diagnosis, major discordance occurs in a significant number of cases, including highly treatable diseases such as acute promyelocystic leukemia and hairy cell leukemia. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

13. Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin's Lymphomas (NHLs).

Author

Hosing, Chitra, Munsell, Mark, Popat, Uday, Körbling, Martin, Valverde, Rosamar, Maadani, Farzaneh, Kebriaei, Partow, Alousi, Amin, DeLima, Marcos, McMannis, John, Shpall, Elizabeth J., Qazilbash, Muzaffar H., Anderlini, Paolo, Giralt, Sergio, Champlin, Richard, and Khouri, Issa

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results